Publications 2024

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
JCI Insight, 9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731

Publications 2023

Vilming B, Fallås Dahl J, Bentzen AG, Ingebrigtsen VA, Berge Nilsen E, Vistad I, Dørum A, Solheim O, Bjørge L, Zucknick M, Aune G, Lindemann K (2023)
Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer
Int J Gynecol Cancer, 33 (12), 1898-1905
DOI 10.1136/ijgc-2023-004484, PubMed 38000795

Publications 2022

Madland K, Bjorge L, Småstuen MC, Dørum A, Vistad I (2022)
Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?
Int J Gynecol Cancer (in press)
DOI 10.1136/ijgc-2022-003361, PubMed 35680138

O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A (2022)
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Gynecol Oncol, 166 (1), 36-43
DOI 10.1016/j.ygyno.2022.04.012, PubMed 35550709

Publications 2021

Gansmo LB, Sofiyeva N, Bjørnslett M, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2021)
Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
Sci Rep, 11 (1), 23463
DOI 10.1038/s41598-021-02820-z, PubMed 34873230

Helwa R, Gansmo LB, Bjørnslett M, Halle MK, Werner HMJ, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2021)
Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer
Biomarkers, 26 (4), 302-308
DOI 10.1080/1354750X.2021.1891291, PubMed 33645339

Sert BM, Kristensen GB, Kleppe A, Dørum A (2021)
Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience
Gynecol Oncol, 162 (2), 284-291
DOI 10.1016/j.ygyno.2021.05.028, PubMed 34083029

Publications 2020

Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA (2020)
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
Gynecol Oncol, 159 (2), 442-448
DOI 10.1016/j.ygyno.2020.09.006, PubMed 32981695

Rolfsen ALD, Dahl AA, Pripp AH, Dørum A (2020)
Base rate of ovarian cancer on algorithms in patients with a pelvic mass
Int J Gynecol Cancer, 30 (11), 1775-1779
DOI 10.1136/ijgc-2020-001416, PubMed 32699016

Salminen L, Nadeem N, Rolfsen AL, Dørum A, Laajala TD, Grènman S, Hietanen S, Heinosalo T, Perheentupa A, Poutanen M, Bolstad N, Carpén O, Lamminmäki U, Pettersson K, Gidwani K, Hynninen J, Huhtinen K (2020)
Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses
J Appl Lab Med, 5 (2), 263-272
DOI 10.1093/jalm/jfz012, PubMed 32445385

Zubor P, Wang Y, Liskova A, Samec M, Koklesova L, Dankova Z, Dørum A, Kajo K, Dvorska D, Lucansky V, Malicherova B, Kasubova I, Bujnak J, Mlyncek M, Dussan CA, Kubatka P, Büsselberg D, Golubnitschaja O (2020)
Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology
Int J Mol Sci, 21 (21)
DOI 10.3390/ijms21217988, PubMed 33121141

Publications 2019

Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA (2019)
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Gynecol Oncol, 152 (3), 560-567
DOI 10.1016/j.ygyno.2018.12.009, PubMed 30638768

Publications 2018

Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S (2018)
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
Ann Intern Med, 168 (5), 326-334
DOI 10.7326/M17-0101, PubMed 29335712

Publications 2017

Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2017)
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
BMC Cancer, 17 (1), 97
DOI 10.1186/s12885-017-3094-y, PubMed 28158999

Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R (2017)
TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch, 470 (6), 665-678
DOI 10.1007/s00428-017-2127-x, PubMed 28432432

Johansen N, Liavaag AH, Iversen OE, Dørum A, Braaten T, Michelsen TM (2017)
Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
Acta Obstet Gynecol Scand, 96 (5), 547-555
DOI 10.1111/aogs.13120, PubMed 28236297

Landskron J, Kraggerud SM, Wik E, Dørum A, Bjørnslett M, Melum E, Helland Ø, Bjørge L, Lothe RA, Salvesen HB, Taskén K (2017)
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
PLoS One, 12 (7), e0182030
DOI 10.1371/journal.pone.0182030, PubMed 28759630

Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G (2017)
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Br J Cancer, 116 (4), 455-463
DOI 10.1038/bjc.2016.435, PubMed 28118323

Vistad I, Bjørge L, Solheim O, Fiane B, Sachse K, Tjugum J, Skrøppa S, Bentzen AG, Stokstad T, Iversen GA, Salvesen HB, Kristensen GB, Dørum A (2017)
A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
Acta Obstet Gynecol Scand, 96 (10), 1162-1169
DOI 10.1111/aogs.13199, PubMed 28795770

Publications 2016

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S (2016)
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
Tumour Biol, 37 (8), 10697-702
DOI 10.1007/s13277-016-4940-2, PubMed 26867771

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J et al. (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
N Engl J Med, 375 (22), 2154-2164
DOI 10.1056/NEJMoa1611310, PubMed 27717299

Publications 2015

Bjørnslett M, Dahl AA, Sørebø Ø, Dørum A (2015)
Psychological distress related to BRCA testing in ovarian cancer patients
Fam Cancer, 14 (4), 495-504
DOI 10.1007/s10689-015-9811-2, PubMed 25980896

Publications 2012

Bjørnslett M, Knappskog S, Lønning PE, Dørum A (2012)
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
BMC Cancer, 12, 454
DOI 10.1186/1471-2407-12-454, PubMed 23039163

Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E, Norwegian Breast Cancer Group trial NBCG VI, Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE (2012)
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
PLoS One, 7 (4), e36263
DOI 10.1371/journal.pone.0036263, PubMed 22558411

Michelsen TM, Dørum A, Cvancarova M, Liavaag AH, Dahl AA (2012)
Association between hysterectomy with ovarian preservation and cardiovascular disease in a Norwegian population-based sample
Gynecol Obstet Invest, 75 (1), 61-7
DOI 10.1159/000345072, PubMed 23220872

Publications 2011

Dahl AA, Gudbergsson SB, Dørum A, Fosså SD, Liavaag AH, Sørebø Ø (2011)
"The impact of cancer scale" version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors
Qual Life Res, 21 (8), 1459-70
DOI 10.1007/s11136-011-0053-y, PubMed 22045155

Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS et al. (2011)
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
Cancer Cell, 19 (2), 273-82
DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605

Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E, Gynecologic Cancer Intergroup (2011)
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
Ann Oncol, 22 (11), 2417-2423
DOI 10.1093/annonc/mdr001, PubMed 21402619

Publications 2010

Michelsen TM, Tonstad S, Pripp AH, Tropé CG, Dørum A (2010)
Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer
Int J Gynecol Cancer, 20 (2), 233-9
DOI 10.1111/igc.0b013e3181ca5ff4, PubMed 20169665

Publications 2009

Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2009)
Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors
BMC Cancer, 9, 2
DOI 10.1186/1471-2407-9-2, PubMed 19121203

Liavaag AH, Tonstad S, Pripp AH, Tropé C, Dørum A (2009)
Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study
Int J Gynecol Cancer, 19 (4), 634-40
DOI 10.1111/IGC.0b013e3181a13058, PubMed 19509562

Michelsen TM, Dørum A, Dahl AA (2009)
A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer
Gynecol Oncol, 113 (1), 128-33
DOI 10.1016/j.ygyno.2008.12.024, PubMed 19178933

Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA (2009)
Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer
Int J Gynecol Cancer, 19 (6), 1029-36
DOI 10.1111/IGC.0b013e3181a83cd5, PubMed 19820364

Publications 2008

Dørum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA (2008)
Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2)
Gynecol Oncol, 109 (3), 377-83
DOI 10.1016/j.ygyno.2008.02.025, PubMed 18407340

Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P (2008)
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers
J Med Genet, 46 (9), 593-7
DOI 10.1136/jmg.2008.058248, PubMed 18413372

Michelsen TM, Pripp AH, Tonstad S, Tropé CG, Dørum A (2008)
Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study
Eur J Cancer, 45 (1), 82-9
DOI 10.1016/j.ejca.2008.09.028, PubMed 19008092

Publications 2007

Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C, Dahl AA (2007)
A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach
Gynecol Oncol, 108 (2), 348-54
DOI 10.1016/j.ygyno.2007.10.009, PubMed 17996925

Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2007)
Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?
J Clin Oncol, 25 (15), 2049-56
DOI 10.1200/JCO.2006.09.1769, PubMed 17513809

Publications 2006

Aghmesheh M, Suo Z, Friedlander M, Nesland JM, Kaern J, Stewart M, Kconfab, Dorum A, Tucker KM, Buckley MF (2006)
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas
Pathology, 38 (2), 145-51
DOI 10.1080/00313020600561526, PubMed 16680901

Knudsen A, Monstad SE, Dørum A, Lønning PE, Salvesen HB, Drivsholm L, Aarseth JH, Vedeler CA (2006)
Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
Cancer Immunol Immunother, 55 (10), 1280-4
DOI 10.1007/s00262-006-0121-2, PubMed 16429314

Monstad SE, Storstein A, Dørum A, Knudsen A, Lønning PE, Salvesen HB, Aarseth JH, Vedeler CA (2006)
Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique
Clin Exp Immunol, 144 (1), 53-8
DOI 10.1111/j.1365-2249.2006.03031.x, PubMed 16542365

Sert B, Abeler VM, Dørum A, Trope CG (2006)
A new approach to treatment of early-stage cervical carcinoma: entire laparoscopic abdominal radical hysterectomy with bilateral pelvic lymphadenectomy without vaginal cuff closure--case reports
Eur J Gynaecol Oncol, 27 (5), 513-8
PubMed 17139990

Publications 2005

Davidson B, Xi Z, Klokk TI, Tropé CG, Dørum A, Scheistrøen M, Saatcioglu F (2005)
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
Am J Clin Pathol, 123 (3), 360-8
DOI 10.1309/PTBB-5BPC-KX8K-9V69, PubMed 15716231

Dørum A, Blom GP, Ekerhovd E, Granberg S (2005)
Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study
Am J Obstet Gynecol, 192 (1), 48-54
DOI 10.1016/j.ajog.2004.07.038, PubMed 15672002

Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A (2005)
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
BMC Cancer, 5, 134
DOI 10.1186/1471-2407-5-134, PubMed 16229746

Publications 2004

Aghmesheh M, Nesland JM, Kaern J, Dorum A, Edwards L, Byth K, Friedlander M, Jackson P, Tucker KM, Russell PJ (2004)
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers
Gynecol Oncol, 95 (3), 430-6
DOI 10.1016/j.ygyno.2004.08.035, PubMed 15581943

Bjørge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, Langseth H, Nustad K, Tropé CG, Dørum A (2004)
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study
Br J Cancer, 91 (10), 1829-34
DOI 10.1038/sj.bjc.6602199, PubMed 15477862

Ekstrøm PO, Bjørge T, Dørum A, Longva AS, Heintz KM, Warren DJ, Hansen S, Gislefoss RE, Hovig E (2004)
Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis
Anal Chem, 76 (15), 4406-9
DOI 10.1021/ac049788k, PubMed 15283579

Publications 2001

Dørum A (2001)
Hereditary ovarian cancer in Norway
Unit of Medical Genetics and Department of Gynecologic Oncology, The Norwegian Radium Hospital, Oslo, 1 b. (flere pag.)
BIBSYS 010513000, ISBN 82-7722-132-0

Publications 2000

Bjørge T, Dørum A, Tropé CG (2000)
[Screening for ovarian cancer]
Tidsskr Nor Laegeforen, 120 (12), 1444-8
PubMed 10851943

Publications 1999

Borg A, Dørum A, Heimdal K, Maehle L, Hovig E, Møller P (1999)
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations
Dis Markers, 15 (1-3), 79-84
DOI 10.1155/1999/278269, PubMed 10595257

Dørum A, Heimdal K, Hovig E, Inganäs M, Møller P (1999)
Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer
Am J Hum Genet, 65 (3), 671-9
DOI 10.1086/302530, PubMed 10441573

Dørum A, Heimdal K, Løvslett K, Kristensen G, Hansen LJ, Sandvei R, Schiefloe A, Hagen B, Himmelmann A, Jerve F, Shetelig K, Fjaerestad I, Tropé C, Møller P (1999)
Prospectively detected cancer in familial breast/ovarian cancer screening
Acta Obstet Gynecol Scand, 78 (10), 906-11
DOI 10.1034/j.1600-0412.1999.781013.x, PubMed 10577622

Dørum A, Hovig E, Tropé C, Inganas M, Møller P (1999)
Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA
Eur J Cancer, 35 (5), 779-81
DOI 10.1016/s0959-8049(99)00050-7, PubMed 10505039

Heimdal K, Apold J, Maehle L, Dørum A, Møller P (1999)
[Hereditary breast cancer in Norway]
Tidsskr Nor Laegeforen, 119 (26), 3929-32
PubMed 10592755

Publications 1998

Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjaerg L, Dørum A, Møller P, Weber BL, Børresen-Dale AL (1998)
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening
Hum Mutat, 11 (2), 166-74
DOI 10.1002/(SICI)1098-1004(1998)11:2<166::AID-HUMU10>3.0.CO;2-X, PubMed 9482581

Dørum A, Heimdal K, Møller P (1998)
Clinical implications of BRCA1 genetic testing
Acta Obstet Gynecol Scand, 77 (4), 458-61
PubMed 9598958

Moller P, Maehle L, Heimdal K, Dorum A, Apold J, Engebretsen LF, Kaurin RM, Jorgensen OG, Helgerud P, Qvist H, Bjorndal H, Kullmann G, Bohler P, Nysted A, Soreide JA, Varhaug JE, Aas T, Fjosne HE, Hagen A, Due J, Karesen R, Formoe E, Malme PA, Stedjeberg JO, Svenningsen SS et al. (1998)
Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer
Breast, 7 (1), 55-59
DOI 10.1016/S0960-9776(98)90053-4

Narod SA, Risch H, Moslehi R, Dørum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA (1998)
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group
N Engl J Med, 339 (7), 424-8
DOI 10.1056/NEJM199808133390702, PubMed 9700175

Smith-Sørensen B, Kaern J, Holm R, Dørum A, Tropé C, Børresen-Dale AL (1998)
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
Br J Cancer, 78 (3), 375-81
DOI 10.1038/bjc.1998.502, PubMed 9703286

Publications 1997

Dørum A, Abeler VM, Heimdal K, Tropé C, Møller P (1997)
The problem of skipped generation and subclinical disease in familial breast-ovarian cancer
Acta Obstet Gynecol Scand, 76 (2), 166-8
DOI 10.3109/00016349709050074, PubMed 9049291

Dørum A, Møller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Tropé CG, van der Hout AH, van der Meulen MA, Buys CH, te Meerman GJ (1997)
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing
Eur J Cancer, 33 (14), 2390-2
DOI 10.1016/s0959-8049(97)00328-6, PubMed 9616287

Publications 1996

Dørum A, Kristensen GB, Abeler VM, Tropé CG, Møller P (1996)
Early detection of familial ovarian cancer
Eur J Cancer, 32A (10), 1645-51
DOI 10.1016/0959-8049(96)00137-2, PubMed 8983269

Møller P, Maehle L, Heimdal K, Dørum A, Tretli S, Helgerud P, Quist H, Bjørndal H, Kåresen R, Nysted A, Varhaug JE, Fjøsne HE, Guleng RJ, Due J, Bøhler P, Giercksky KE, Tropé C, Kvinnsland S (1996)
Inherited breast carcinoma--prospective findings in 1,194 women at risk
Acta Oncol, 35 Suppl 8, 7-11
DOI 10.3109/02841869609098515, PubMed 9073043

Saetersdal A, Dørum A, Heimdal K, Helgerud P, Sager EM, Bøhler P, Tretli S, Kvinnsland S, Møller P (1996)
Inherited predisposition to breast carcinoma. Results of first round examination of 537 women at risk
Anticancer Res, 16 (4A), 1989-92
PubMed 8712731

Publications 1994

Dørum A, Kristensen GB, Tropé C (1994)
A randomised study of cisplatin versus thiotepa as induction chemotherapy in advanced ovarian carcinoma
Eur J Cancer, 30A (10), 1470-4
DOI 10.1016/0959-8049(94)00240-6, PubMed 7833104

Publications 1993

Dørum A, Kristensen GB, Langebrekke A, Sørnes T, Skaar O (1993)
Evaluation of endometrial thickness measured by endovaginal ultrasound in women with postmenopausal bleeding
Acta Obstet Gynecol Scand, 72 (2), 116-9
DOI 10.3109/00016349309023423, PubMed 8383406

KRISTENSEN G, DORUM A (1993)
EVALUATION OF ENDOMETRIUM WITH TRANSVAGINAL ULTRASOUND - REPLY
Acta Obstet. Gynecol. Scand., 72 (8), 687
DOI 10.3109/00016349309021170

Publications 1991

Dørum A, Nesheim BI (1991)
Monochorionic monoamniotic twins--the most precarious of twin pregnancies
Acta Obstet Gynecol Scand, 70 (4-5), 381-3
DOI 10.3109/00016349109007895, PubMed 1746268